Streptavidin: SureLight™ APC kinase assay format, 1mg

$333.00

SKU: D3-2212-K01 Category:

Description

Streptavidin conjugated to SureLight™ APC – Optimized for kinase assays, 1mg

Binding Moiety: Streptavidin

Uses: Optimized for High throughput screening (HTS) and fluorescence resonance energy transfer (FRET) assays targeting kinase activity, flow cytometry

 

Reviews

There are no reviews yet.

Be the first to review “Streptavidin: SureLight™ APC kinase assay format, 1mg”

Your email address will not be published. Required fields are marked *

Size:
1mg
Dye:
SureLight™ Allophycocyanin
Excitation max. λ:
652nm
Emission max. λ:
657.5nm
Form / Storage:
Lyophilized, Store at 4° C.
Stability:

Upon reconstitution, product should be stored at 4° C and used within 8 months.

Technical Info:

References

  • Auclair, D., Miller, D., Yatsula, V., Pickett, W., Carter, C., Chang, Y., et al. (2007). Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia (Vol. 21).
  • Bader, B., Butt, E., Palmetshofer, A., Walter, U., Jarchau, T., & Drueckes, P. (2001). A cGMP-dependent protein kinase assay for high throughput screening based on time-resolved fluorescence resonance energy transfer. J Biomol Screen (Vol. 6).
  • Bamborough, P., Angell, R. M., Bhamra, I., Brown, D., Bull, J., Christopher, J. A., et al. (2007). N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics. Bioorganic & Medicinal Chemistry Letters (Vol. 17).
  • Barrios Sosa, A. C., Boschelli, D. H., Ye, F., Golas, J. M., & Boschelli, F. (2004). Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles. Bioorganic & Medicinal Chemistry Letters (Vol. 14).
  • Crombie, A. L., Sum, F. – W., Powell, D. W., Hopper, D. W., Torres, N., Berger, D. M., et al. (2010). Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorganic & Medicinal Chemistry Letters.
  • Emmitte, K. A., Wilson, B. J., Baum, E. W., Emerson, H. K., Kuntz, K. W., Nailor, K. E., et al. (2009). Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). Bioorganic & Medicinal Chemistry Letters (Vol. 19).
  • Freiberg, G., Wilkins, J., David, C., Kofron, J., Jia, Y., Hirst, G. C., et al. (2004). Utilization of microarrayed compound screening (microARCS) to identify inhibitors of p56lck tyrosine kinase. J Biomol Screen (Vol. 9).
  • Jin, G., Aulabaugh, A., Pocas, J., Liu, H., Kriz, R., & Sampath, D. (2006). Development and comparison of nonradioactive in vitro kinase assays for NIMA-related kinase 2. Anal Biochem (Vol. 358).
  • Kuroda, K., Kobayashi, K., Kitagawa, Y., Nakagawa, T., Tsumura, H., Komeda, T., et al. (2008). Efficient Antibody Production upon Suppression of O Mannosylation in the Yeast Ogataea minuta. Appl Environ Micro (Vol. 74).
  • Li, M., Luraghi, P., Amour, A., Qian, X. – D., Carter, P. S., Clark, C. J., et al. (2009). Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates, Anal Biochem (Vol. 384).
  • Lindqvist, L., Oberer, M., Reibarkh, M., Cencic, R., Bordeleau, M. – E., Vogt, E., et al. (2008). Selective Pharmacological Targeting of a DEAD Box RNA Helicase. PLoS ONE (Vol. 3).
  • Moshinsky, D. J., Ruslim, L., Blake, R. A., & Tang, F. (2003). A Widely Applicable, High-Throughput TR-FRET Assay for the Measurement of Kinase Autophosphorylation: VEGFR-2 as a Prototype. J Biomol Screen (Vol. 8).
  • Patnaik, D., Jun Xian,, Glicksman, M. A., Cuny, G. D., Stein, R. L., & Higgins, J. M. G. (2008). Identification of Small Molecule Inhibitors of the Mitotic Kinase Haspin by High-Throughput Screening Using a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer Assay. J Biomol Screen (Vol. 13).
  • Sabbatini, P., Rowand, J. L., Groy, A., Korenchuk, S., Liu, Q., Atkins, C., et al. (2009). Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase. Clin Cancer Res (Vol. 15).
  • Sadler, T. M., Achilleos, M., Ragunathan, S., Pitkin, A., LaRocque, J., Morin, J., et al. (2004). Development and comparison of two nonradioactive kinase assays for I kappa B kinase. Anal Biochem (Vol. 326).
  • Schlapbach, A., Feifel, R., Hawtin, S., Heng, R., Koch, G., Moebitz, H., et al. (2008). Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity. Bioorganic & Medicinal Chemistry Letters (Vol. 18).
  • Vassilev, L. T., Tovar, C., Chen, S., Knezevic, D., Zhao, X., Sun, H., et al. (2006). Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. PNAS (Vol. 103).
  • Velcicky, J., Feifel, R., Hawtin, S., Heng, R., Huppertz, C., Koch, G., et al. (2010). Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy. Bioorganic & Medicinal Chemistry Letters (Vol. 20).
  • Wang, Y., Shakespeare, W. C., Huang, W. – S., Sundaramoorthi, R., Lentini, S., Das, S., et al. (2008). Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters (Vol. 18).
  • Wei, M., Wynn, R., Hollis, G., Liao, B., Margulis, A., Reid, B. G., et al. (2007). High-Throughput Determination of Mode of Inhibition in Lead Identification and Optimization. J Biomol Screen (Vol. 12).
  • Zhang, W. – G., Shor, B., & Yu, K. (2006). Identification and characterization of a constitutively T-loop phosphorylated and active recombinant S6K1: Expression, purification, and enzymatic studies in a high capacity non-radioactive TR-FRET Lance assay. Protein Expression and Purification (Vol. 46).
  • Zhang, W. X., Wang, R., Wisniewski, D., Marcy, A. I., LoGrasso, P., Lisnock, J. – M., et al. (2005). Time-resolved Forster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38alpha protein kinase. Anal Biochem (Vol. 343).